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Jacob and Speed did not identify even a single example of a ‘150-gene-set’ that was statistically significant at
classifying Alzheimer’s disease (AD) samples, or age in independent studies. We attempt to clarify the various
misunderstandings, below.In 2013 we discovered a 150 RNA ‘gene-set’ from healthy
skeletal muscle (others named HAG) that proved to be a
high performing, statistically significant, non-linear age
classifier of multiple types of human tissue [1]. We pro-
filed muscle samples from an independent birth cohort
and found our HAG score correlated with ‘successful
aging’ over two decades, using rank-order methods
which incorporated the direction of gene expression
change from the original model [1]. The following year,
we found that the HAG score was regulated with age in
human hippocampus and in human blood profiles from
AD [1]. Since then over 50 HAG have been linked, by
other laboratories, to the biology of age and dementia
(see Additional file 1), robust confirmation of the bio-
logical validity of the HAG. We illustrated the potential
utility of the HAG, by combining it with a set of AD reg-
ulated ‘disease’ genes [2] to yield a test that distinguished
AD samples from age- and gender-matched controls
(Sood et al Fig. 5 [1]). The original disease signature (the
Lunnon et al AD signature [2]) was not statistically
significant, on its own, in an independent AD cohort.
Notably this 150 probe-set plus 48 gene prototype ‘AD
blood assay’ (red-dot, Age+AD-disease) out performs all© The Author(s). 2019 Open Access This artic
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and remains one of the only RNA assays validated in an
independent AD cohort. We presented our transcrip-
tomic age model as a logical starting point for machine
learning requiring independent data, to produce a tool
to facilitate clinical AD research (i.e. screen for acceler-
ated ‘aging’, the risk factor for AD).
Substantial misunderstandings of our article, by Jacob
and Speed, led to them create a narrative through refer-
ence to Ein-Dor et al [Ref 2 in their letter], that our
work was an example of a classification solution found
using a small clinical cohort [3]. Typically such solutions
do not transfer to independent clinical cohorts, because
the model is over-fitted to all the characteristics of the
first data set. Notably it was impossible for the HAG sig-
nature to belong to this category, as we did not select
our gene list using an AD cohort. Importantly, our single
HAG ‘150 gene list’ was confirmed to be statistically
significant in two independent AD cohorts [1]. In
contrast, Jacob and Speed calculated thousands of ROC
values; did not apply any statistical test for significance,
and never confirmed the performance of any of their
gene lists in any independent cohorts. For clarity on this
complex topic, Table 1 contrasts some of the major
differences in approach and rigor, taken by our team
versus the approach presented by Jacob and Speed. It is
noteworthy that the approach we took is far more
laborious, and we understand why Jacob and Speed may
have chosen to skip over most of the following time
consuming and important steps.le is distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 A guide to the graphing layouts produced by Jacob and Speed and bench-marking against our top-ranked AD signature. a Using the same
code and sampling procedure as Jacob and Speed, we compare the top-ranked gene-set from Fig. 5 Sood et al. [1] with their performance of their
random process. Critically, Jacob’s code creates two random sampling objects per R session – rand.sig.1 for GSE63060 and rand.sig.2 for GSE63061,
reflecting the different gene content of the GSE63060 and GSE63061 arrays. Jacob and Speed do not implement any cross-cohort validation nor any
consideration of correction for multiple testing. Notably, our top-ranked blood signature exceeds random sampling by a substantial margin and
critically is ‘active’ in both blood data-sets. Note that their ‘random’ gene-lists are selected from entire gene-chip which contains thousands of
published age and AD correlated genes (as listed in our 2015 article, supplementary information). b Using the same code and sampling
procedure as Jacob and Speed, we present the performance of just the 150 tissue age genes from Sood et al. (blue dot) in blood. We then assess
one example of choices made by Jacob and Speed, namely using 50 vs 75% cohort split during withincohort cross-validation. By selecting a 50%
split the relative (to ‘random’) performance of our age-150 gene list is impaired. Since the Sood age-150 was never stated to be the only age
classifier, we made a genuine attempt at sampling at random by removing known Age (and AD) genes from the sampling pool (as listed in our
2015 article, supplementary information [1]). As Jacob’s code does not implement any cross-cohort validation nor any consideration of correction
for multiple testing, our age signature remains the only signature validated in two (blood) cohorts (and across other independent data)
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computational code, and found that their within-cohort
modeling of the AD data (an approach we did not use as
it is unreliable [4] (Table 1)) yielded 150 gene-sets with
performance that reflected laboratory batch-noise within
the AD Illumina blood RNA arrays (AdNeuroMed con-
sortium [2]). We illustrate this, by sampling using their
code, but only from non-expressed (‘background’) genes
(Additional file 1: Figure S1). This noise is unfortunate,
but the illustration demonstrates that the performance
of their random sampling protocol was not driven, asTable 1 A comparison of the approaches of Sood et al. and Jacob
Performance criteria
Hypothesis driven gene selection in independent samples
Tissue age ROC performance externally validated
Multi-tissue age classification achieved
Longitudinal health association achieved
Top age gene-set statistically tested in blood
ROC performance assessed within an AD cohort
Top gene-set statistically significant across AD cohorts
Top gene-set independently linked to age and dementia
Gene-set trained in AD clinical cohortclaimed, to ‘interconnected biology’ or ‘shared gene ex-
pression variance’. Furthermore, their claim that our
150-gene age signature (Fig. 1b, blue-dot) lay ‘within’ the
performance range obtained via random sampling in
blood is neither correct nor a fair like-for-like statistical
comparison [4]. Our single 150 HAG test was statisti-
cally significant in two independent AD cohorts, and
exceeded any background noise. Jacob and Speed random
gene-sets require statistical correction for thousands of
multiple-tests and notably they did not present any
statistical significance values. The importance of ourand Speed
Sood et al. Jacob and Speed
Yes No
Yes No
Yes No
Yes No
Yes No
Yes Yes
Yes No
Yes No
No Yes
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external validation (i.e. using independent data to validate
a model) over their ‘easy to perform’ within data sampling
is neither controversial or recent knowledge - See Konig
et al. and cited articles [4].
We also found that their (less reliable) ‘within co-
hort’ ROC performance approach was enhanced by
some of their choices e.g. 50% data-splits resulted in
~ 10% gain in ROC value, in their favor (Fig. 1b).
Their random gene lists were not actually ‘random’
from a biological perspective. Sampling occurred from
known age and AD correlated genes (see methods).
Removal of age and AD genes known at the time of
our study (2015) also reduces the performance of
sampling at random (Additional file 1: Figure S2).
Curiously, Jacob and Speed did not match AD cases
with controls, for chronological age and gender (the
two greatest risk factors for AD). Instead they combined AD
with the Mild Cognitive Impairment (MCI) samples - a
heterogenous population, comprising several clinical condi-
tions and many who never develop AD [5]. This was clinic-
ally invalid but also unnecessary, as all required information
was included in the GEO repository e.g. age, gender and
clinical sample status (embedded in GSE63060 and
GSE63061 as visualized in his files supplied with their letter
(Additional file 1: Figure S3)). Combining the AD and MCI
clinical samples also exaggerated the within cohort perform-
ance of their approach while it impaired the performance of
our top-ranked gene-set (Additional file 1: Figure S4). Critic-
ally Jacob and Speed should have been able to replicate the
design of our study analysis as all data necessary was at
GEO, as illustrated in Additional file 1: Figure S3 - a screen
shot taken directly from implementing the code provided by
Jacob and Speed.
Finally, Jacob and Speed have claimed that our tis-
sue age model was itself ‘unremarkable’. A clue to
the exceptional performance of our age signature was
the observation that when using muscle RNA profiles
as the external validation data (classification space),
the age of brain samples was classified correctly [1].
However, we formally revisited this issue by compar-
ing our [1] HAG signature with 10,000 gene-sets
chosen at random from the same muscle cohort. We
calculated performance of each recorded ‘at random’
gene-set, using cross-cohort ‘gold standard’ external
validation (four independent muscle data-sets; code
and methods are included in the Additional file 1).
Our 150 HAG signature was ranked better than all
10,000 ‘random’ gene-sets (Additional file 1: Figure
S5A). We calculated the statistical significance of the
average ‘random’ gene-set, and the performance of an
‘age model selected at random’ was not significant
(unadjusted p = 0.113), despite having an ROC value
> 0.6. Even gene-sets discovered and tested within asingle cohort were largely inferior to our age signa-
ture (Additional file 1: Figure S5B). Our observations
lead to the conclusion that the claims made by Jacob
and Speed are flawed, at least in part because they
did not present a single example of a new 150-gene-
set that significantly worked across independent data
as a tissue age classifer, a muscle-based health prog-
nostic or a blood AD classifier. Thus, while we agree
with Ein-Dor et al, that classifiers built on small clin-
ical cohorts should be treated with caution; reflecting
the interactive network of tissue and cellular gene ex-
pression [6] and simple technical factors such as
noise, as we did not build a disease classifier using
AD or any other disease samples, we find Jacob and
Speed's criticism [3] of our work unfounded.
Additional file
Additional file 1: Supplementary figures S1-S5, Supplementary Methods
and code. (DOCX 3780 kb)
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